Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke.

@article{Williams2012PreclinicalSA,
  title={Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke.},
  author={Patricia D Williams and Berislav V Zlokovic and John H. Griffin and Kent E Pryor and Thomas P Davis},
  journal={Current pharmaceutical design},
  year={2012},
  volume={18 27},
  pages={
          4215-22
        }
}
Activated protein C (APC), a protease with anticoagulant and cytoprotective activities, protects neurons and cerebrovascular endothelium from ischemic injury. A recombinant APC, drotrecogin alfa (activated) (DrotAA) (Xigris®), was approved by the Food and Drug Administration for the treatment of sepsis; however, serious bleeding was a dose-limiting side effect. A modified APC, containing 405 amino acid residues, 3K3A-APC, was designed to possess significantly reduced anticoagulant activity… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
Blog posts, news articles and tweet counts and IDs sourced by
Altmetric.com